Omega Diagnostics CEO (LON:ODX) Colin King introduces the business to Proactive London's Andrew Scott and its main areas of focus - CD4, infectious diseases and food intolerance testing. He says while some areas of the business have been slowed by the pandemic they're rapidly developing new tests for COVID-19 that will need to be made and sold in significant volume.
Omega Diagnostics to expand manufacturing capacity as it scales up coronavirus test development
Quick facts: Omega Diagnostics Group PLC
Price: 51.65 GBX
Market Cap: £90.71 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE